<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574128</url>
  </required_header>
  <id_info>
    <org_study_id>ECC 2020</org_study_id>
    <nct_id>NCT04574128</nct_id>
  </id_info>
  <brief_title>Retransfusion or Not of Cardiotomy Blood</brief_title>
  <official_title>Blood Loss With Cardiopulmonary Bypass, Re-transfusion or Not.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised controlled trial has a non-inferiority design. The aim is to test if the&#xD;
      blood loss (volume in mL and hemoglobin) is effected by heart and lung cardiotomy&#xD;
      retransfusion, or not? Forty CABG (Coronary Artery By pass Grafting) patients will be&#xD;
      allocated to either receive retransfusion (n=20) of cardiotomy blood via the heart and lung&#xD;
      mashine, or no retransfusion (n=20).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomised controlled non-inferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The person that controle the heart- and lung mashine is not masked. Other members of the surgical team is masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>blood loss</measure>
    <time_frame>During 5 days hemoglobin will be measured as the clinical rutine or as needed.</time_frame>
    <description>Hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>During 2 days or while surgical drains remains, blood volume in mL is measured.</time_frame>
    <description>Blood volume in millilitre (mL)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <arm_group>
    <arm_group_label>Retransfusion of cardiotomy blood or not</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group does not get cardiotomy blood retransfusion via heart-and lung machine while control does.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No retransfusion of cardiotomy blood</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No retransfusion of cardiotomy blood</intervention_name>
    <description>No retransfusion of cardiotomy blood via heart- and lung mashine</description>
    <arm_group_label>Retransfusion of cardiotomy blood or not</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective CABG.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anaemia, infection, massive bleeding, CABG off pump.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camilla Wistrand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örebro University, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla Wistrand, PhD</last_name>
    <phone>+460707686938</phone>
    <email>camilla.wistrand@regionorebrolan.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital in Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Camilla Wistrand, PhD</last_name>
      <phone>+46707686938</phone>
      <email>camilla.wistrand@regionorebrolan.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The datasets generated and/or analysed during the current study are not publicly available due to ethical considerations of the participant integrity. Bacterial growth can be seen as sensitive data. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

